Forgot your password?

Forgot your username?

database > company
DARA BioSciences, Inc.
Biotech Specialty Pharma
8601 Six Forks Road, Suite 160
Raleigh, NC 27615 USA
phone:(919) 872-5578
fax:
Symbol DARA
Exchange Nasdaq
Founded 2002
Employees 6
www.DaraBio.com
Research Sector Biotech Specialty Pharma
Summary Description
Acquires promising therapeutic small molecules and develops them through proof of concept in humans.
Management
Richard A. Franco, President, CEO & Chairman of the Board; Ann A. Rosar, Chief Accounting Officer; Linda G. Jett,Clinical Director; Mary K. Delmedico, Project Leader/Program Manager; Lynn Morris, Sr. Manager Investor Relations & Corporate Operations
Ownership
Financials Mkt Cap :12
* numbers in thousands
 

Keywords
neuropathic pain; chemotherapy induced peripheral neuropathy; diabetes, psoriasis; oncology; nephrology; dermatology; stem cells; KRN5500; DB959: metabolic diseases; central nervous system; DB200

Comment | Printable Version | Modify profile |
Updated: Sept. 20, 2011

Description
DARA BioSciences, Inc. is a Raleigh, North Carolina based biopharmaceutical development company that acquires promising therapeutic candidates and develops them through proof of concept in humans for subsequent sale or out-licensing to larger pharmaceutical companies. Presently DARA has two drug candidates with cleared IND (Investigational New Drug) Applications from the United States FDA and are in clinical study. The Company has a pipeline of diverse drug candidates at various stages of development, with 82 granted patents and 56 pending applications (U.S. and foreign). The first drug candidate KRN5500 has successfully completed a Phase 2 clinical trial treating cancer patients for neuropathic pain. KRN5500 met its primary endpoint and was statistically significantly (p=0.03) better than placebo. A second Phase 2 clinical trial is planned to start during the second half of 2010. The second drug candidate DB959 is a highly selective, non-thiazolidinedione (TZD), first-in-class dual PPAR (peroxisome proliferator activated receptor) delta/gamma agonist in development for type II diabetes. A Phase 1 clinical study for DB959 is underway and the Company plans to announce results in the second half of 2010. In addition, DARA owns CPT-1 inhibitors intended for topical application for patients with psoriasis, a library of DDPIV inhibitors and a diverse library of approximately 1800 PPAR agonists of various molecular modalities. PPAR receptors are found throughout the human body and recent publications report that PPAR agonists may be useful in the treatment of Alzheimer's disease, cystic fibrosis, liver disease, and a variety of autoimmune diseases. Because its diverse PPAR library has the potential to address the unmet medical needs of these diseases, the company plans to explore several of these indications.
Products / Services
Small molecule development of potential treatments for central nervous system disorders including neuropathic pain, metabolic diseases, and dermatological conditions.
Technology / Differentiation
DARA develops promising therapuetic candidates through proof of concept in humans which has the least amount of risk and monetary requirements while accelerating revenues.
Market / Customers
Mid and large pharma companies worldwide.
Strategy
DARA BioSciences? development and liquidity strategy for each entity will vary depending on market conditions, stage of development, the target profile of product candidates in the pipeline and the competitive market dynamic.
Status
Presently DARA has two drug candidates with cleared IND (Investigational New Drug) Applications from the United States FDA and are in clinical study. The first drug candidate KRN5500 has successfully completed a Phase 2 clinical trial treating cancer patients for neuropathic pain. KRN5500 met its primary endpoint and was statistically significantly (p=0.03) better than placebo. A second Phase 2 clinical trial is planned to start during the second half of 2010. The second drug candidate DB959 is a highly selective, non-thiazolidinedione (TZD), first-in-class dual PPAR (peroxisome proliferator activated receptor) delta/gamma agonist in development for type II diabetes. A Phase 1 clinical study for DB959 is underway and the Company plans to announce results in the second half of 2010. The Company has a pipeline of diverse drug candidates at various stages of development, with 82 granted patents and 56 pending applications (U.S. and foreign). In addition, DARA owns CPT-1 inhibitors intended for topical application for patients with psoriasis, a library of DDPIV inhibitors and a diverse library of approximately 1800 PPAR agonists of various molecular modalities. PPAR receptors are found throughout the human body and recent publications report that PPAR agonists may be useful in the treatment of Alzheimer's disease, cystic fibrosis, liver disease, and a variety of autoimmune diseases. Because its diverse PPAR library has the potential to address the unmet medical needs of these diseases, the company plans to explore several of these indications.